Enigma and Beijing Leadman Form Infectious Disease Diagnostic JV

Enigma Diagnostics of England announced a joint venture with Beijing Leadman Biochemistry for China development of Enigma's molecular diagnostic point-of-care (PoC) infectious disease test. Beijing Leadman will market the Enigma Mini Laboratory PoC molecular diagnostic system in China, while Enigma will out-license China rights for its technology to the JV. The JV will develop molecular assays specifically for the China market and manufacture the tests in China. In addition, Enigma  signed a $50 million subscription agreement with Sailing Capital of Shanghai to market the system in Europe. More details.... Stock Symbol: (SHE: 300289) Share this with colleagues: // //  
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.